The most recent issue of The Napeague Letter contained the following thoughts about CLZR:
CANDELA CORPORATION - CLZR:
CLZR's primary business seems to be doing fine and looks like it is on
track. However, the Company's new venture is absorbing much of the
Company's cash flow and is reducing its profits substantially, and it
appears to be relatively high risk in nature.
The Company has put out several press releases recently. On May 22nd,
the Company announced that the FDA had cleared its new Skinscan
product, "a microprocessor- driven skin scanning device used for
aesthetic laser surgery." This release can be found at biz.yahoo.com. On May 28th, the
Company announced that "it is a recipient of Photonics Spectra's
Photonics Circle of Excellence Award in recognition of Candela's
ScleroPLUS(tm), an advanced cosmetic and medical laser system." This
can be found at biz.yahoo.com.
I am currently reviewing its most recent 10-Q Report, and expect to
have my updated Analysis completed within a day or two. I am trying
to isolate the potential value of the chain of LaserSpas that the
Company is developing, and hopefully will be able to bring this to
bear on the Analysis. Once again, I am "suspending judgment" until I
complete this review.
After approaching the $9.00 level in February, CLZR has been drifting
downwards, to around $5.25 by mid-May. As a result of the May 22nd
announcement, the stock staged a fairly impressive but short-lived
rally, but this quickly lost momentum and the stock has now dropped
back to $6.75.
A complete, but not-yet-up-to-date Analysis of CLZR can be found at napeague.com |
